Critical Review: ProQR Therapeutics (NASDAQ:PRQR) versus Exelixis (NASDAQ:EXEL)

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) and Exelixis (NASDAQ:EXEL – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Institutional and Insider Ownership

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

ProQR Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Profitability

This table compares ProQR Therapeutics and Exelixis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ProQR Therapeutics -205.69% -72.78% -36.78%
Exelixis 35.45% 45.54% 33.90%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ProQR Therapeutics and Exelixis, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProQR Therapeutics 1 0 6 1 2.88
Exelixis 1 10 6 1 2.39

ProQR Therapeutics presently has a consensus target price of $7.60, suggesting a potential upside of 439.01%. Exelixis has a consensus target price of $58.62, suggesting a potential downside of 15.05%. Given ProQR Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe ProQR Therapeutics is more favorable than Exelixis.

Valuation and Earnings

This table compares ProQR Therapeutics and Exelixis”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ProQR Therapeutics $18.36 million 8.09 -$47.73 million ($0.46) -3.07
Exelixis $2.50 billion 6.74 $782.57 million $3.34 20.66

Exelixis has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Summary

Exelixis beats ProQR Therapeutics on 9 of the 13 factors compared between the two stocks.

About ProQR Therapeutics

(Get Free Report)

ProQR Therapeutics N.V. is a biotechnology company developing RNA-based medicines for genetic diseases. Its research centers on Axiomer, a platform designed to make targeted changes to RNA using the body’s naturally occurring editing machinery. Founded in 2012 and based in Leiden, the Netherlands, ProQR initially focused on RNA therapies for inherited retinal disorders, including Usher syndrome and Leber congenital amaurosis. The company later broadened its emphasis to RNA editing and continues to develop potential treatments for genetic conditions.

About Exelixis

(Get Free Report)

Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.